127 related articles for article (PubMed ID: 15240740)
1. Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute.
Ida K; Kawaguchi S; Sato Y; Tsukahara T; Nabeta Y; Sahara H; Ikeda H; Torigoe T; Ichimiya S; Kamiguchi K; Wada T; Nagoya S; Hiraga H; Kawai A; Ishii T; Araki N; Myoui A; Matsumoto S; Ozaki T; Yoshikawa H; Yamashita T; Sato N
J Immunol; 2004 Jul; 173(2):1436-43. PubMed ID: 15240740
[TBL] [Abstract][Full Text] [Related]
2. Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma.
Sato Y; Nabeta Y; Tsukahara T; Hirohashi Y; Syunsui R; Maeda A; Sahara H; Ikeda H; Torigoe T; Ichimiya S; Wada T; Yamashita T; Hiraga H; Kawai A; Ishii T; Araki N; Myoui A; Matsumoto S; Umeda T; Ishii S; Kawaguchi S; Sato N
J Immunol; 2002 Aug; 169(3):1611-8. PubMed ID: 12133991
[TBL] [Abstract][Full Text] [Related]
3. SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group.
Kawaguchi S; Tsukahara T; Ida K; Kimura S; Murase M; Kano M; Emori M; Nagoya S; Kaya M; Torigoe T; Ueda E; Takahashi A; Ishii T; Tatezaki S; Toguchida J; Tsuchiya H; Osanai T; Sugita T; Sugiura H; Ieguchi M; Ihara K; Hamada K; Kakizaki H; Morii T; Yasuda T; Tanizawa T; Ogose A; Yabe H; Yamashita T; Sato N; Wada T
Cancer Sci; 2012 Sep; 103(9):1625-30. PubMed ID: 22726592
[TBL] [Abstract][Full Text] [Related]
4. Substitution analog peptide derived from HER-2 can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.
Mimura K; Kono K; Southwood S; Fikes J; Takahashi A; Miyagawa N; Sugai H; Fujii H
Cancer Immunol Immunother; 2006 Nov; 55(11):1358-66. PubMed ID: 16435129
[TBL] [Abstract][Full Text] [Related]
5. Characterization of cytomegalovirus pp65-HLA-A24 peptide-specific CTL lines from metastatic melanoma patients.
Akiyama Y; Tai S; Komiyama M; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y
Oncol Rep; 2009 Jul; 22(1):185-91. PubMed ID: 19513522
[TBL] [Abstract][Full Text] [Related]
6. Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma.
Kawaguchi S; Wada T; Ida K; Sato Y; Nagoya S; Tsukahara T; Kimura S; Sahara H; Ikeda H; Shimozawa K; Asanuma H; Torigoe T; Hiraga H; Ishii T; Tatezaki SI; Sato N; Yamashita T
J Transl Med; 2005 Jan; 3(1):1. PubMed ID: 15647119
[TBL] [Abstract][Full Text] [Related]
7. Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes.
Kikuchi M; Nakao M; Inoue Y; Matsunaga K; Shichijo S; Yamana H; Itoh K
Int J Cancer; 1999 May; 81(3):459-66. PubMed ID: 10209962
[TBL] [Abstract][Full Text] [Related]
8. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
[TBL] [Abstract][Full Text] [Related]
9. Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients.
Kobayashi J; Torigoe T; Hirohashi Y; Idenoue S; Miyazaki A; Yamaguchi A; Hiratsuka H; Sato N
J Transl Med; 2009 Jan; 7():1. PubMed ID: 19123955
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215
[TBL] [Abstract][Full Text] [Related]
11. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
12. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner.
Kontani K; Teramoto K; Ozaki Y; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Yokomise H; Ohkubo I
Int J Oncol; 2004 Dec; 25(6):1537-42. PubMed ID: 15547688
[TBL] [Abstract][Full Text] [Related]
13. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24.
Tanaka F; Fujie T; Tahara K; Mori M; Takesako K; Sette A; Celis E; Akiyoshi T
Cancer Res; 1997 Oct; 57(20):4465-8. PubMed ID: 9377553
[TBL] [Abstract][Full Text] [Related]
14. Identification of the HLA-A24 peptide epitope within cytomegalovirus protein pp65 recognized by CMV-specific cytotoxic T lymphocytes.
Masuoka M; Yoshimuta T; Hamada M; Okamoto M; Fumimori T; Honda J; Oizumi K; Itoh K
Viral Immunol; 2001; 14(4):369-77. PubMed ID: 11792066
[TBL] [Abstract][Full Text] [Related]
15. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs.
Gomi S; Nakao M; Niiya F; Imamura Y; Kawano K; Nishizaka S; Hayashi A; Sobao Y; Oizumi K; Itoh K
J Immunol; 1999 Nov; 163(9):4994-5004. PubMed ID: 10528204
[TBL] [Abstract][Full Text] [Related]
16. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes.
Arai J; Yasukawa M; Ohminami H; Kakimoto M; Hasegawa A; Fujita S
Blood; 2001 May; 97(9):2903-7. PubMed ID: 11313288
[TBL] [Abstract][Full Text] [Related]
17. A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells.
Miyagawa N; Kono K; Mimura K; Omata H; Sugai H; Fujii H
Oncology; 2006; 70(1):54-62. PubMed ID: 16446550
[TBL] [Abstract][Full Text] [Related]
18. Analysis of individual specific cytotoxic T lymphocytes for two MAGE-3-derived epitopes presented by HLA-A24.
Katsura F; Eura M; Chikamatsu K; Oiso M; Yumoto E; Ishikawa T
Jpn J Clin Oncol; 2000 Mar; 30(3):117-21. PubMed ID: 10798537
[TBL] [Abstract][Full Text] [Related]
19. Cytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptide.
Matsunaga K; Nakao M; Masuoka K; Inoue Y; Gouhara R; Imaizumi T; Nishizaka S; Itoh K
Jpn J Cancer Res; 1999 Sep; 90(9):1007-15. PubMed ID: 10551332
[TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes.
Yamada A; Kawano K; Koga M; Matsumoto T; Itoh K
Cancer Res; 2001 Sep; 61(17):6459-66. PubMed ID: 11522641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
